Robert C. Flexon has served as the CEO of Dyne Therapeutics, Inc. since it emerged from bankruptcy in 2012. With a robust background in the energy sector, he oversaw the company’s shift towards a more sustainable business structure. Before joining...

Robert C. Flexon has served as the CEO of Dyne Therapeutics, Inc. since it emerged from bankruptcy in 2012. With a robust background in the energy sector, he oversaw the company’s shift towards a more sustainable business structure. Before joining Dynegy, he held notable positions at UGI Corporation and NRG Energy, gaining extensive experience in finance and operations. Flexon’s tenure is marked by strategic growth, and his leadership in transforming Dyne into a competitive player in the energy market is evident from his performance-driven compensation structure. In 2023, he earned a total compensation of $1,090,684, a combination of salary, bonuses, and other benefits reflecting the company's performance. Interestingly, Flexon has actively participated in buying Dyne’s stock, indicating confidence in the company’s future. His investments actually peaked around 2024, showcasing an upward trend in his stock ownership that aligns with the company’s recovery and growth over a decade. With a career spanning over many years in progressive roles, he combines strategic foresight with hands-on experience.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Dyne Therapeutics, Inc. CEOs

D

Robert C. Flexon

CEO of Dyne Therapeutics, Inc.

Field of Expertise

Energy & Utilities - Energy

Sector of Economy

Healthcare

CEO of Dyne Therapeutics, Inc. for

13 years 5 months (Jan 2012 - Present)

Previous Experience

Various roles in the energy sector, including as President and COO of Dynegy.

Rivals

Competitors/colleagues of Robert C. Flexon

Holdings

See how much did Robert C. Flexon make over time.

Robert C. Flexon has consistently invested in Dyne Therapeutics’ stock, reflecting his belief in the company's mission. His holdings saw significant appreciation, especially between 2020 and 2024, when monthly stock purchases rose from $184,370 to over $2 million. In 2024...

Robert C. Flexon has consistently invested in Dyne Therapeutics’ stock, reflecting his belief in the company's mission. His holdings saw significant appreciation, especially between 2020 and 2024, when monthly stock purchases rose from $184,370 to over $2 million. In 2024 alone, he made purchases that exceeded $1.88 million, showcasing his strong commitment to the company's future. Flexon’s investments highlight a steady increase in stock value, with a notable peak in his purchasing activity indicating growing confidence as the company recovered from its tumultuous past. This trend demonstrates not just his strategic acumen but also his alignment with shareholder interests that likely boosted morale among investors and staff.

No data yet.

Insider Trading

See recent insider trades of Robert C. Flexon.

DYN

$107.40K

DYN at $7.16/share

Mar 24, 2017

Purchase

DYN

$190.50K

DYN at $7.62/share

Mar 8, 2017

Purchase

DYN

228,330 shares

DYN

Mar 1, 2017

Received

DYN

$102.68K

DYN at $8.21/share

Nov 4, 2016

Purchase

DYN

$100.80K

DYN at $10.08/share

Mar 1, 2016

Purchase

DYN

$167.00K

DYN at $16.70/share

Nov 13, 2015

Purchase

DYN

$183.28K

DYN at $22.91/share

Aug 12, 2015

Purchase

DYN

$649.60K

DYN at $32.48/share

May 12, 2015

Purchase

DYN

153,563 shares

DYN

May 11, 2015

Received

DYN

60,261 shares

DYN

Mar 3, 2015

Received

Compensation History

See how much did Robert C. Flexon make over time.

In 2023, Robert C. Flexon earned a total compensation of $1,090,684, consisting of a base salary of $643,550, a performance-based bonus of $460,138, and other benefits. His bonus was tied to meeting specific corporate goals, showing a clear link between his pay and the company's success. Flexon’s compensation reflects the changing dynamics and challenges in the energy industry, rewarding him for driving Dyne's performance during a critical period. This trend continued from past years, where he reported compensation figures that included stock options and combined incentives, culminating in one of his best earnings in 2015 with over $12 million. However, recent years have shown a shift towards more sustainable salary structures that reward performance without relying heavily on stock grants.

Year

2023

Total Compensation

$1.10M

Salary

$643.55K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on motivating executives to achieve short- and long-term results.

Bonus

$460.14K

Board Justification

Performance-based cash bonuses awarded based on corporate and individual performance for the year 2023.

Other

$996.00

Board Justification

Other compensation includes long-term disability insurance premiums and group term life insurance premiums in excess of statutory limits.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2023 for Robert C. Flexon.

Performance Metrics

Performance metrics for bonuses are based on corporate goals and individual performance.

Other Dyne Therapeutics, Inc. CEOs

Here are other CEOs of Dyne Therapeutics, Inc.

Thomas W. Elward

CEO of Dyne Therapeutics, Inc.

December 2011 - Invalid Date

Lawrence Klein

CEO of Dyne Therapeutics, Inc.

May 2023 - Present